Nitrogen-containing three-fused-ring PRMT5 inhibitor as well as preparation method and pharmaceutical application thereof
Patent Information
- Application Number
- CN202380033447.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-22
- Filing Date
- 2023-06-26
- Publication Date
- 2024-11-29
AI Technical Summary
Current technologies struggle to target PRMT5 in MTAP-deficient tumor cells while avoiding side effects in normal cells, resulting in a limited therapeutic window for PRMT5 inhibitors.
Develop a nitrogen-containing triple-fused-ring PRMT5 inhibitor that selectively targets PRMT5 in the MTA-bound state, enriching only in MTAP-deficient tumor cells and reducing its impact on normal cells.
It provides a therapeutic window for effectively inhibiting PRMT5 in MTAP-deficient tumor cells, reduces side effects on normal cells, and has broad potential for treating and preventing PRMT5-mediated diseases.
Smart Images

Figure CN119053603A_ABST
Abstract
Description
A nitrogen-containing tri-fused ring PRMT5 inhibitor, its preparation method and pharmaceutical use Technical Field
[0001] The present invention belongs to the field of drug synthesis, and specifically relates to a nitrogen-containing tri-fused-ring PRMT5 inhibitor, a preparation method thereof, and pharmaceutical uses. Background Art
[0002] Epigenetic gene regulation is an important biological regulatory mechanism for protein synthesis and cell differentiation, and plays an important role in many human diseases.
[0003] Epigenetic regulation involves the manipulation of inherited genetic material without altering its nucleic acid sequence. Typically, epigenetic regulation is achieved by selective and reversible modifications (e.g., methylation) of DNA and proteins (e.g., histones) to control the transition between transcriptionally active and inactive states of chromatin conformation. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., PRMT5), many of which are associated with specific genetic alterations in numerous human disease-causing genes. PRMT5 plays a crucial role in numerous diseases, including cancer, metabolic disorders, and hematologic diseases.
[0004] Homozygous deletion of tumor suppressor genes is a tumor driver and often results in the loss of nearby passenger genes. Loss of these passenger genes confers tumor cell-specific vulnerabilities that can be targeted with targeted therapies. Homozygous deletion of chromosome 9p21, encompassing the well-known tumor suppressor gene CDKN2A, occurs in 15% of tumors and often includes loss of the passenger gene MTAP. MTAP is a key enzyme in the methionine and adenine recycling pathway. Loss of MTAP leads to the accumulation of its substrate, MTA. MTA shares structural similarities with S-adenosylmethionine (SAM), the methyl group donor for the type II methyltransferase PRMT5. Elevated MTA levels due to MTAP loss selectively compete with SAM for PRMT5 binding, rendering the methyltransferase inactive and susceptible to PRMT5 inhibition. A variety of genome-wide shRNA screens across a wide range of tumor cell lines have demonstrated a correlation between MTAP deficiency and cell line dependence on PRMT5, placing the impact of this metabolic vulnerability in the spotlight. However, as PRMT5 is a critical gene for cells, studies using conditional knockout or siRNA knockdown of PRMT5 have suggested that inhibiting PRMT5 in normal tissues can have significant side effects (e.g., cytopenias, infertility, skeletal muscle loss, cardiac hypertrophy, etc.). Therefore, new strategies are needed to exploit and explore this metabolic vulnerability, selectively targeting PRMT5 in MTAP-deficient tumors while avoiding its effects in normal tissues (MTAP wild-type).
[0005] Small molecule inhibitors targeting PRMT5 that collaborate with MTA can selectively target only PRMT5 in the MTA-bound state, and this PRMT5 is only enriched in tumor cells that lack MTAP. Therefore, in normal cells with intact MTAP, when MTA levels are very low, PRMT5 will not be targeted, thus providing a better therapeutic window.
[0006] Summary of the Invention
[0007] The present invention aims to provide a nitrogen-containing tri-fused ring PRMT5 inhibitor, its preparation method, and pharmaceutical uses. The compounds of this invention have a strong inhibitory effect on PRMT5 and can be widely used to prepare drugs for treating and / or preventing PRMT5-mediated diseases, thus potentially leading to the development of a new generation of PRMT5 inhibitors.
[0008] The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0009] in, is a double bond or a single bond;
[0010] X1 is C or N, X2 is C or N, provided that at least one of X1 and X2 is N;
[0011] X3 is CR5 or N, X4 is CR6 or N, X5 is CR7 or N,
[0012] X6 is CR8 or N, X7 is CR9 or N, X8 is CR 10 or N;
[0013] R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0014] R is -Ring A-(Ra ) n ,
[0015] Ring A is selected from C 3-12 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-12 The cycloalkyl group or the 4-10 membered heterocyclic group is optionally further fused to a C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is optionally further fused to 5-10 membered heteroaryl, C 3-12 Cycloalkyl or 4-10 membered heterocyclic group,
[0016] Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 , or, when n ≥ 2, two R aTogether with the carbon atom to which it is directly attached, it forms C(O), and the above groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0017] R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R 15 、-OR 14 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R17 , the C 3-12 The cycloalkyl group or the 3-12 membered heterocyclic group is optionally further fused to a C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 The aryl or 5-10 membered heteroaryl is optionally further fused to a C 3-12 Cycloalkyl or 4-10 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0018] R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;
[0019] R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0020] R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、 -C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0021] Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 , or, R 11 and R 12 Together with the carbon atom to which it is directly connected, it forms a C 3-12 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0022] Each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0023] Each R 14 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0024] Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0025] Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or
[0026] R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent;
[0027] m is 0, 1, or 2;
[0028] n is 0, 1, 2, 3, 4, 5 or 6;
[0029] Each r is independently 0, 1 or 2.
[0030] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R3 and R4 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent;
[0031] Among them, R 16 and R 17 As described for the compound of formula (I).
[0032] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R3 and R4 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
[0033] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R5, R6 and R7 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0034] Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0035] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R5, R6 and R7 are independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0036] Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0037] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0038] Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0039] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0040] Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0041] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、 -C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 , or, R 11 and R 12 Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0042] Among them, R 13 、R14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0043] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0044] Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r are as described for the compound of formula (I).
[0045] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15substituted by a substituent;
[0046] R is -Ring A-(R a ) n , wherein ring A is selected from C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 The cycloalkyl group or the 4-8 membered heterocyclic group is optionally further fused to a C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to 5-8 membered heteroaryl, C 3-6 Cycloalkyl or 4-8 membered heterocyclic group,
[0047] Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0048] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R 15 、-OR 14 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent;
[0049] Among them, R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、R 17, m, n and r are as described for the compound of formula (I).
[0050] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0051] Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0052] Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent;
[0053] Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or
[0054] R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-8 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.
[0055] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following compound structure of formula (II):
[0056] wherein X3 is CR5 or N, X4 is CR6 or N, X5 is CR7 or N, X6 is CR8 or N, and X7 is CR9 or N;
[0057] R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0058] R is the following structure:
[0059] Among them, Y1, Y2, Y4, Y5, Y6, Y7, Y8, Y9, Y 10 、Y 11 、Y 12 、Y 13 Each independently CR a or N; Y3 is -O-, -S- or -NR a3 -; Z is -O-, -S-, or -CR a1 R a2 -、-CR a1 R a2 -O- or -NR a3 -, p is 0, 1, 2 or 3;
[0060] Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0061] Each R a1 and R a2 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0062] Each R a3 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0063] Each R2 is independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 Alkyl substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent;
[0064] R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;
[0065] R8 and R9 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;
[0066] Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ;
[0067] Among them, R 13 、R 14 、R 15 、R 16 、R 17 , r and m are as described for the compound of formula (I).
[0068] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, has the following structures of formula (III1) and formula (III2):
[0069] wherein each X3 is independently CR5 or N, each X4 is independently CR6 or N, each X5 is independently CR7 or N, and each X6 is independently CR8 or N;
[0070] In the structure of the compound of formula (III2), ring B is a 4-10 membered nitrogen-containing heterocyclic group, and the 4-8 membered nitrogen-containing heterocyclic group is optionally further substituted by one or more selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -NR 16 R 17 substituted by a substituent;
[0071] Each R is independently the following structure:
[0072] Among them, Y1, Y2, Y6, Y7, Y8, Y9, Y 10 and Y 11 Each independently CR a or N; Y3 is -O- or -S-; Z is -O-, -S-, -CH2- or -CH2-O-, p is 0, 1, 2 or 3,
[0073] Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OR 14 、-C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;
[0074] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 Alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -SF5, -OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent;
[0075] Each of R5, R6 and R7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ;
[0076] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ;
[0077] Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ;
[0078] Among them, R 14 、R 15 、R 16 and R 17 As described for the compound of formula (I).
[0079] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the structure of which contains Selected from the following structures:
[0080] Each X6 is independently CR8 or N;
[0081] Each of R5, R6 and R7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5, amino, single C 1-4 Alkyl substituted amino and di-C 1-4 Alkyl substituted amino group;
[0082] Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5, amino, single C 1-4 Alkyl substituted amino and di-C 1-4 Alkyl substituted amino group.
[0083] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) has the following formula (IV 1-1 )、(Ⅳ 1-2 )、(Ⅳ 2-1 ) or (Ⅳ 2-2 )Compound structure:
[0084] wherein each X4 is independently CR6 or N; each X5 is independently CR7 or N;
[0085] Y6 and Y7 are each independently CH or N; Z is O or CH2; p is 1 or 2;
[0086] Formula (Ⅳ 2-1 ) or (Ⅳ 2-2 ) In the compound structure, ring B and its substituents are selected from the following structures:
[0087] q is selected from 0, 1 or 2;
[0088] Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, methoxy, ethoxy, cyclopropyl and -SF5;
[0089] Each R" is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl and cyclopropyl;
[0090] Each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl and triazinyl, and the above groups are independently optionally further substituted by one or more deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuterated methyl substituted by alkyl, dideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, phenyl, pyrazolyl, 2-(trimethylsilyl)ethoxy, methyl-substituted pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, fluorine-substituted pyridyl, pyridazinyl, pyrimidinyl, triazinyl, =O, =S, -SF5, hydroxy, methoxy, ethoxy, cyclopropyloxy, cyclobutyloxy, amino, methylamino, and dimethylamino substituents;
[0091] Each R a each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, trifluoromethoxy, trideuteromethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, methyl-substituted cyclopropyl, methyl-substituted cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, tetrahydropyrrolyl, piperidinyl, methyl-substituted piperidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyrimidinyl, methyl-substituted pyrazolyl, -SF5, hydroxyl, amino, methylamino, dimethylamino, dimethylaminomethyl and dimethylaminoethyl;
[0092] Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl;
[0093] Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl;
[0094] Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl;
[0095] R 11 and R 12 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
[0096] As a further preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the structure of which contains Selected from the following structures:
[0097] R7 is selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0098] R8 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
[0099] As a further preferred embodiment, among the compounds of formula (I), their stereoisomers or pharmaceutically acceptable salts thereof, the compounds of formula (IV 1-2 ) and (Ⅳ 2-1 ) contained in the compound structure Selected from the following structures:
[0100] Formula (Ⅳ 1-1 ) contained in the compound structure Selected from the following structures:
[0101] Each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, isopropyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5.
[0102] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrazolyl, imidazolyl, thiazolyl, pyridyl and pyrimidinyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, , cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrazolyl, (2-(trimethylsilyl)ethoxy)methyl substituted pyrazolyl, imidazolyl, thiazolyl, pyridinyl, fluorine substituted pyridinyl, pyrimidinyl, methoxy, ethoxy and cyclopropyloxy substituents.
[0103] As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, trifluoromethyl, trifluoroethyl, trideuteriomethyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl or the following substituent structures:
[0104] As a further preferred embodiment, the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, the compound of formula (I) has the following formula (V 1-1-1 ) or formula (V 1-1-2 )Compound structure:
[0105] wherein each Y7 is independently CH or N; each Z is independently O or CH2; each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5;
[0106] Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0107] Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0108] wherein R2 is as described for the compound of formula (I).
[0109] As a further preferred embodiment, the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, the compound of formula (I) has the following formula (V1-2-1 ) or formula (V 1-2-2 )Compound structure:
[0110] Wherein, Y6 and Y7 are each independently CH or N; R a is selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl, and -SF5;
[0111] R7 is selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0112] R8 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
[0113] As a further preferred embodiment, the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, the compound of formula (I) has the following formula (V 2-1-1 ) or formula (V 2-1-2 )Compound structure:
[0114] Among them, each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5;
[0115] Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0116] Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0117] Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl.
[0118] As a further preferred embodiment, the compound of formula (I), its stereoisomer or its pharmaceutically acceptable salt, the compound of formula (I) has the following formula (V 2-2-1 ) or formula (V 2-2-2 )Compound structure:
[0119] Among them, each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl, methyl-substituted piperidinyl, dimethylaminoethyl and -SF5;
[0120] Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0121] Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl;
[0122] Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl.
[0123] As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:
[0124] The third aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0125] The fourth aspect of the present invention provides the use of a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating MATP-related tumors.
[0126] As a further preferred embodiment, the tumor is selected from the group consisting of cell tumors, lymphomas, leukemias, osteomas, malignant teratomas, intraepithelial carcinomas, adenomas, fibromas, melanomas, fallopian tube cancer, bladder cancer, teratomas, embryonal carcinomas, choriocarcinomas, lipomas, liver cancer, bile duct cancer, lung cancer, gastric cancer, hemangiomas, gallbladder cancer, ampullary cancer, malignant melanomas, nevi, dysplastic nevi, myeloproliferative diseases, Hodgkin's disease, chordomas, myxomas, rhabdomyomas, leiomyomas, hamartomas, mesotheliomas, insulinomas, glucagonomas, gastrinomas, carcinoid tumors, viper tumors, granulomas, xanthomas, osteitis deformans, ependymomas, neurilemmomas, congenital tumors, meningiomas, gliomas, skin cancers, head and neck cancers, and sarcomas.
[0127] As a further preferred embodiment, the cell tumor is selected from granulosa-thecoma cell tumor, Sertoli cell tumor, germ cell tumor, Wilms tumor, seminoma, hepatoblastoma, malignant fibrous histiocytoma, chondroblastoma, giant cell tumor, astrocytoma, medulloblastoma, glioblastoma multiforme, oligodendroglioma, retinoblastoma, squamous cell carcinoma, clear cell carcinoma, transitional cell carcinoma, interstitial cell carcinoma and basal cell carcinoma;
[0128] The lymphoma is selected from malignant lymphoma and non-Hodgkin's lymphoma;
[0129] The leukemia is selected from acute and chronic myeloid leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia;
[0130] The bone tumor is selected from osteochondroma, benign enchondroma, osteoid osteoma, enchondromatous hamartoma, multiple myeloma and skull tumor;
[0131] The adenoma is selected from the group consisting of fibroadenoma, adenomatoid tumor, hepatocellular adenoma, bronchial adenoma, tubular adenoma, villous adenoma, breast cancer, pancreatic cancer, endometrial adenocarcinoma, prostate cancer, ductal adenocarcinoma and colorectal adenocarcinoma;
[0132] The fibroma is selected from the group consisting of fibroma, chondromyxofibroma, neurofibroma and spinal neurofibroma;
[0133] The myeloproliferative disease is selected from the group consisting of multiple myeloma and myelodysplastic syndrome;
[0134] The lung cancer is selected from bronchogenic carcinoma and alveolar carcinoma;
[0135] The sarcoma is selected from the group consisting of fibrosarcoma, botryoid sarcoma, angiosarcoma, Kaposi's sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, and meningeal sarcoma.
[0136] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, which are used as PRMT5 inhibitor drugs.
[0137] The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts, which are used as PRMT5 inhibitor drugs.
[0138] The present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases.
[0139] The present invention also relates to a method for treating and / or preventing a disease mediated by PRMT5, comprising administering a therapeutically effective amount of the compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a patient in need thereof. DETAILED DESCRIPTION
[0140] After extensive and in-depth research, the inventors of this application have developed for the first time a PRMT5 inhibitor having the structure of Formula (I) below. The compounds of this invention can be widely used in the preparation of drugs for treating and / or preventing PRMT5-mediated diseases and are expected to be developed into a new generation of PRMT5 inhibitors. Based on this, the present invention was completed.
[0141] Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.
[0142] "Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched alkyl group having 1 to 10, 1 to 6, or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl , 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or its various branched chain isomers, etc. “C 1-10 "Alkyl" refers to a straight chain alkyl group or a branched chain alkyl group containing 1 to 10 carbon atoms. 1-4 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups containing 1 to 4 carbon atoms, "C 0-8 "Alkyl" refers to straight chain alkyl and branched chain alkyl groups including 0 to 8 carbon atoms, "C 0-4 The term "alkyl" refers to straight-chain and branched-chain alkyl groups having 0 to 4 carbon atoms.
[0143] Alkyl groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0144] "Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl is divided into monocyclic cycloalkyl and polycyclic cycloalkyl, preferably a cycloalkyl containing 3 to 12, 3 to 8 or 3 to 6 carbon atoms, for example, "C 3-12 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 12 carbon atoms, "C 4-8 "Cycloalkyl" refers to a cycloalkyl group comprising 4 to 8 carbon atoms, "C 3-8 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 8 carbon atoms, "C 3-6 "Cycloalkyl" refers to a cycloalkyl group comprising 3 to 6 carbon atoms, wherein:
[0145] Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.
[0146] Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:
[0147] "Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:
[0148] "Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:
[0149] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.
[0150] "Cycloalkyl" or "carbocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O)r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0151] "Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) r (wherein r is an integer of 0, 1, or 2), but excluding the ring portion of -OO-, -OS-, or -SS-, the remaining ring atoms are carbon. Preferably, the heterocyclyl group comprises 3 to 12, 3 to 8, or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 6 ring atoms, "3-8 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 8 ring atoms, "4-8 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 8 ring atoms, "4-10 membered heterocyclyl" refers to a heterocyclyl group comprising 4 to 10 ring atoms, "5-8 membered heterocyclyl" refers to a heterocyclyl group comprising 5 to 8 ring atoms, and "3-12 membered heterocyclyl" refers to a heterocyclyl group comprising 3 to 12 ring atoms.
[0152] Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.
[0153] Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which the single rings share an atom (called a spiro atom), wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O). r (where r is an integer 0, 1, or 2) with the remaining ring atoms being carbon. These may contain one or more double bonds (preferably 1, 2, or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are classified as monospiro heterocyclic groups, dispiro heterocyclic groups, or polyspiro heterocyclic groups based on the number of spiro atoms shared between the rings. Spiro heterocyclic groups include, but are not limited to:
[0154] "Fused heterocyclyl" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with the other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused heterocyclic groups include, but are not limited to:
[0155] "Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, these may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) r (where r is an integer of 0, 1, or 2) and the remaining ring atoms are carbon. Depending on the number of rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged heterocyclic groups include, but are not limited to:
[0156] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:
[0157] "Heterocyclyl" or "heterocycle" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0158] "Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably an all-carbon aromatic group containing 6-10 or 6-8 carbon atoms, for example, "C 6-10 "Aryl" refers to an all-carbon aromatic group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl. 6-8 "Aryl" refers to an all-carbon aromatic group containing 6-8 carbon atoms. The aromatic ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aromatic ring, including but not limited to:
[0159] "Aryl" or "aromatic ring" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0160] "Heteroaryl" or "heteroaromatic ring" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N·O and S(O)r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:
[0161] "Heteroaryl" or "heteroaromatic ring" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、 -C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0162] "Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight or branched alkenyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkenyl" refers to a straight or branched chain alkenyl containing 2 to 10 carbon atoms. 2-4 "Alkenyl" refers to a straight or branched chain alkenyl group containing 2 to 4 carbon atoms, including but not limited to ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc.
[0163] "Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0164] "Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight or branched chain alkynyl group containing 2-10 or 2-4 carbon atoms, for example, "C 2-10 "Alkynyl" refers to a straight or branched chain alkynyl containing 2 to 10 carbon atoms. 2-4 "Alkynyl" refers to a straight or branched chain alkynyl containing 2-4 carbon atoms, including but not limited to ethynyl, 1-propynyl, 2-propynyl, 1-, 2- or 3-butynyl, etc.
[0165] "Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0166] "Alkoxy" refers to an -O-alkyl group, wherein alkyl is as defined above, for example, "C 1-10 "Alkoxy" refers to an alkyloxy group containing 1 to 10 carbon atoms. 1-4 "Alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms. 1-2 The term "alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.
[0167] "Alkoxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0168] "Cycloalkoxy" or "cycloalkyloxy" refers to an -O-cycloalkyl group, wherein cycloalkyl is as defined above, for example, "C 3-12 "Cycloalkyloxy" refers to a cycloalkyloxy group containing 3 to 12 carbon atoms. 3-6 The term "cycloalkyloxy" refers to cycloalkyloxy groups containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.
[0169] "Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0170] "Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.
[0171] "Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C 1-10Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent.
[0172] “C 1-10 "Alkanoyl" refers to C 1-10 The monovalent atomic group remaining after removing the hydroxyl group from the alkyl acid is usually expressed as "C 0-9 "C1 alkyl-C(O)-" refers to acetyl; "C2 alkyl-C(O)-" refers to propionyl; "C3 alkyl-C(O)-" refers to butyryl or isobutyryl.
[0173] "-C 0-8 Alkyl-OS(O)2R 13 ” refers to -OS(O)2R 13 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0174] "-C 0-8 Alkyl-S(O) r R 13 ” refers to -S(O) r R 13 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0175] "-C 0-8 Alkyl-OR 14 " refers to -OR 14 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0176] "-C 0-8 Alkyl-C(O)OR 14 " refers to -C(O)OR 14 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0177] "-C 0-8 Alkyl-C(O)SR 14 ” refers to -C(O)SR 14 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0178] "-C 0-8 Alkyl-SC(O)R 15 ” refers to -SC(O)R 15 The sulfur atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0179] "-C 0-8 Alkyl-C(O)R 15 ” refers to -C(O)R 15 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0180] "-C 0-8 Alkyl-OC(O)R 15 ” refers to -OC(O)R 15 The oxygen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0181] "-C0-8 Alkyl-P(O)(R 15 )2” refers to -P(O)(R 15 )2 in which the phosphorus atom is connected to the C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0182] "-C 0-8 Alkyl-NR 16 R 17 ” refers to -NR 16 R 17 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0183] "-C 0-8 Alkyl-C(O)NR 16 R 17 ” refers to -C(O)NR 16 R 17 The carbonyl group is connected to C 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0184] "-C 0-8 Alkyl-N(R 16 )-C(O)R 15 ” refers to -N(R 16 )-C(O)R 15 The nitrogen atom in the 0-8 On the alkyl group, where C 0-8 The alkyl group is as defined above.
[0185] "Halogen-substituted C 1-10 The term "alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl and tribromomethyl.
[0186] "Halogen-substituted C 1-10 "Alkoxy" refers to an alkoxy group of 1-10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms. It includes but is not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy, tribromomethoxy and the like.
[0187] "Deuterium replaces C 1-10 "Alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.
[0188] “Halo” refers to fluorine, chlorine, bromine or iodine, “EA” refers to ethanol, “PE” refers to petroleum ether, “EtOAc” refers to ethyl acetate, “DCM” refers to dichloromethane, “DMSO” refers to dimethyl sulfoxide, “Cs2CO3” refers to cesium carbonate, “ACN” refers to acetonitrile, “Pd(OH)2” refers to palladium hydroxide on carbon, “MeOH” refers to methanol, “rt” refers to room temperature, “1,2-dichlorobenzene” refers to 1,2-dichlorobenzene, “N,N-dimethylaniline” refers to N,N-dimethylaniline, “POCl3” refers to phosphorus oxychloride, “DIPEA” refers to N,N-diisopropylethylamine, “NMP” refers to N-methylpyrrolidone, “TFA” refers to trifluoroacetic acid, “LiOH” refers to lithium hydroxide, “THF” refers to tetrahydrofuran, “PyBrOP” refers to tripyrrolidinium phosphonium bromide hexafluorophosphate, and “DMA” refers to N,N-dimethylacetamide.
[0189] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.
[0190] "Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).
[0191] "Stereoisomers," whose English name is stereoisomer, refer to isomers resulting from the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by rotation about single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, the presence of double bonds or rings in the molecule are called configuration stereoisomers, which are further divided into two categories. Among them, isomers caused by the inability to rotate freely around double bonds or single bonds of ring carbon atoms are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotation properties due to the lack of anti-axial symmetry in the molecule are called optical isomers and are divided into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.
[0192] "Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.
[0193] A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0194] The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.
[0195] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 / 500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (MeOH-d4), and deuterated chloroform (CDCl3) as the solvents, with tetramethylsilane (TMS) as the internal standard.
[0196] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0197] Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0198] The starting materials in the examples of the present invention are known and can be purchased commercially, or can be synthesized using or according to methods known in the art.
[0199] Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).
[0200] Ⅰ. Preparation of intermediates
[0201] Preparation of intermediate 1, 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid
[0202] Step 1: Synthesis of methyl 3-(2-methyl-1H-imidazol-1-yl)-4-nitrobenzoate
[0203] Methyl 3-fluoro-4-nitrobenzoate (1.5 g, 7.54 mmol) and 2-methyl-1H-imidazole (0.74 g, 9.05 mmol) were dissolved in acetonitrile (20 mL). Cesium carbonate (3.69 g, 11.31 mmol) was added and stirred at 80°C overnight. After completion of the reaction, the mixture was quenched with water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford methyl 3-(2-methyl-1H-imidazol-1-yl)-4-nitrobenzoate (1.97 g, 100%), which was used directly in the next step. MS m / z (ESI): 262 [M+H] + .
[0204] Step 2: Synthesis of methyl 4-amino-3-(2-methyl-1H-imidazol-1-yl)benzoate
[0205] Methyl 3-(2-methyl-1H-imidazol-1-yl)-4-nitrobenzoate (1.97 g, 7.54 mmol) was dissolved in methanol (30 mL), and palladium hydroxide (0.4 g, 20% w / w) was added. The mixture was stirred at room temperature overnight. After the reaction, the mixture was filtered and concentrated, and separated by silica gel column chromatography [5% methanol-dichloromethane] to give methyl 4-amino-3-(2-methyl-1H-imidazol-1-yl)benzoate (800 mg, 46%). MS m / z (ESI): 232 [M+H] + .
[0206] Step 3: Synthesis of methyl 1-methyl-4-oxo-4,5-dihydroimidazo[1,5-a]quinoxaline-8-carboxylate
[0207] Methyl 4-amino-3-(2-methyl-1H-imidazol-1-yl)benzoate (800 mg, 3.46 mmol) and di(1H-imidazol-1-yl)methanone (729 mg, 4.50 mmol) were placed in 1,2-dichlorobenzene (30 mL), heated to 160-170°C, and stirred at this temperature for 3 hours. After cooling, the solvent was removed by concentration, and the mixture was slurried in methanol for 10 minutes and filtered to dryness to obtain methyl 1-methyl-4-oxo-4,5-dihydroimidazo[1,5-a]quinoxaline-8-carboxylate (680 mg, 76%). MS m / z (ESI): 258 [M+H] + .
[0208] Step 4: Synthesis of methyl 4-chloro-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate
[0209] Methyl 1-methyl-4-oxo-4,5-dihydroimidazo[1,5-a]quinoxaline-8-carboxylate (680 mg, 2.64 mmol) was placed in phosphorus oxychloride (50 mL), and N,N-dimethylaniline (115.9 mg, 0.53 mmol) was added. The mixture was heated to 120°C and stirred overnight. Some of the starting material remained unreacted. After cooling, the mixture was concentrated and quenched with ice water in an ice-water bath. The mixture was extracted three times with dichloromethane. The combined organic phases were washed with saturated sodium bicarbonate and saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The mixture was then separated by silica gel column chromatography (40-60% ethyl acetate-petroleum ether) to afford methyl 4-chloro-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (460 mg, 63%). MS m / z (ESI): 276 [M+H] + .
[0210] Step 5: Synthesis of methyl 4-((2,4-dimethoxybenzyl)amino)-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate
[0211] Methyl 4-chloro-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (460 mg, 1.67 mmol) was dissolved in N-methylpyrrolidone (8 mL), and 2,4-dimethoxybenzyl)amino (646 mg, 5.01 mmol) was added. The mixture was heated to 110°C and stirred for 3 hours. After completion of the reaction, the mixture was quenched with water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Methyl 4-((2,4-dimethoxybenzyl)amino)-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (605 mg, 89%) was separated by silica gel column chromatography (9% methanol-dichloromethane). MS m / z (ESI): 407 [M+H] + .
[0212] Step 6: Synthesis of methyl 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate
[0213] Methyl 4-((2,4-dimethoxybenzyl)amino)-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (330 mg, 0.81 mmol) was dissolved in trifluoroacetic acid (10 mL) and stirred at 60°C for 6 hours. After the reaction, the mixture was concentrated, an appropriate amount of water was added, and the pH was adjusted to about 6 with aqueous sodium bicarbonate. The mixture was filtered and dried to obtain methyl 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (370 mg crude product). MS m / z (ESI): 257 [M+H] + .
[0214] Step 7: Synthesis of 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid
[0215] Methyl 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylate (370 mg, 0.81 mmol) was dissolved in methanol (10 mL) and tetrahydrofuran (10 mL). Lithium hydroxide monohydrate (102 mg, 2.43 mmol) was added and stirred at 50°C overnight. After the reaction, the mixture was concentrated, an appropriate amount of water was added, and the pH was adjusted to approximately 6 with dilute hydrochloric acid. The filter cake was filtered and washed with water several times. After drying, 4-amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (150 mg, 76%) was obtained. MS m / z (ESI): 243 [M+H] + .
[0216] Intermediates 2 to 7 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 1:
[0217] Preparation of intermediate 8, 4-amino-7-fluoropyrazolo[1,2-a]quinoxaline-8-carboxylic acid
[0218] Step 1: Synthesis of methyl 5-(2-cyano-1H-pyrrol-1-yl)-2-fluoro-4-nitrobenzoate
[0219] Methyl 2,5-difluoro-4-nitrobenzoate (2.0 g, 9.21 mmol) was dissolved in acetonitrile (20 mL), and 1H-pyrrole-2-carbonitrile (0.78 mL, 9.21 mmol) and cesium fluoride (1.40 g, 9.21 mmol) were added. The mixture was stirred at 20°C for 16 hours. The reaction solution was concentrated by rotary evaporation, and the crude product was separated by normal phase column chromatography to obtain methyl 5-(2-cyano-1H-pyrrol-1-yl)-2-fluoro-4-nitrobenzoate (500 mg, 19%).
[0220] 1 H NMR (400MHz, CDCl3) δ8.15(d,J=6.4Hz,1H),7.92(d,J=8.8Hz,1H),7.04(dd,J=4.0 ,1.6Hz,1H),6.93(dd,J=2.8,1.6Hz,1H),6.43(dd,J=4.0,2.8Hz,1H),4.01(s,3H).
[0221] Step 2: Synthesis of methyl 4-amino-7-fluoropyrrolo[1,2-a]quinoxaline-8-carboxylate
[0222] Methyl 5-(2-cyano-1H-pyrrol-1-yl)-2-fluoro-4-nitrobenzoate (1.5 g, 5.19 mmol) was dissolved in tetrahydrofuran (20 mL), and iron powder (2.90 g, 51.86 mmol) and glacial acetic acid (20 mL) were added. The mixture was stirred at 20°C for 16 hours. The reaction solution was evaporated to dryness. The crude product was separated by normal phase column chromatography to afford methyl 4-amino-7-fluoropyrrolo[1,2-a]quinoxaline-8-carboxylate (650 mg, 48%).
[0223] 1 H NMR (400MHz, DMSO-d6) δ8.47(d,J=7.2Hz,1H),8.36(s,1H),7.52(s,2H),7.25-7.06(m,2H),6.75(m,1H),3.88(s,3H).
[0224] Step 3: Synthesis of 4-amino-7-fluoropyrazolo[1,2-a]quinoxaline-8-carboxylic acid
[0225] Methyl 4-amino-7-fluoropyrrolo[1,2-a]quinoxaline-8-carboxylate (600 mg, 2.31 mmol) was dissolved in tetrahydrofuran (10 mL) and water (3 mL). Lithium hydroxide monohydrate (583 mg, 13.89 mmol) was added and the mixture was allowed to react at 50°C for 16 hours. The organic solvent was evaporated under reduced pressure, and water (5 mL) was added. The pH was adjusted to 3-4 with 1M hydrochloric acid, filtered, and the filter cake was washed with water (20 mL) and acetonitrile (20 mL). The filter cake was dried to yield 4-amino-7-fluoropyrazolo[1,2-a]quinoxaline-8-carboxylic acid (341 mg, 60%). MS m / z (ESI): 246 [M+H] + .
[0226] 1 H NMR (400MHz, DMSO-d6) δ9.99(s,1H),9.15(s,1H),8.83-8.53(m,2H),7.79(d,J=3.6Hz,1H),7.57(d,J=10.8Hz,1H),6.94(d,J=3.6Hz,1H).
[0227] Intermediate 9, Preparation of Cyclopropyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine
[0228] Step 1: Synthesis of cyclopropyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine
[0229] Dissolve 5-(Trifluoromethyl)methylpyridinaldehyde (350 mg, 2.0 mmol) in dichloromethane (10 mL), add cyclopropylmethylamine (156 mg, 2.2 mmol) and acetic acid (132 mg, 2.2 mmol), and stir at room temperature for half an hour. Add sodium triacetoxyborohydride (355 mg, 1.68 mmol) and stir at room temperature for one hour. The reaction solution is diluted with dichloromethane and saturated sodium bicarbonate solution, the layers are separated, and the organic phase is concentrated by rotary evaporation. The crude product is separated by column chromatography (methanol / dichloromethane = 1 / 19) to obtain cyclopropyl-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)methanamine (400 mg, 84%). MS m / z (ESI): 231 [M+H] + .
[0230] Intermediates 10 to 19 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of Intermediate 9:
[0231] Preparation of Intermediate 20, 6-(trifluoromethyl)benzofuran-3(2H)-one
[0232] Step 1: Synthesis of methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate
[0233] Methyl 2-hydroxy-4-(trifluoromethyl)benzoate (15.0 g, 68.1 mmol) was dissolved in acetone (200 mL), potassium carbonate (12.24 g, 88.6 mmol) was added, and methyl bromoacetate (8.42 mL, 88.6 mmol) was then added dropwise to the reaction mixture. The temperature was then raised to 55°C and the reaction was allowed to react for 18 hours. After the reaction was complete, the reaction mixture was cooled to room temperature, the solid was filtered out, and the filter cake was washed with ethyl acetate. The filtrate was washed with saturated brine, dried, and concentrated to yield methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate (22.0 g, 94%). MS m / z (ESI): 293 [M+H] + .
[0234] Step 2: Synthesis of 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid
[0235] Methyl 2-(2-methoxy-2-oxoethoxy)-4-(trifluoromethyl)benzoate (74.0 g, 253.2 mmol) was dissolved in a mixture of methanol (500 mL) and water (250 mL). Lithium hydroxide monohydrate (31.91 g, 759.7 mmol) was added and allowed to react at room temperature for 18 hours. The reaction solution was acidified to pH 2 with 1N hydrochloric acid, concentrated to remove methanol, filtered, and the solid washed with water. The filter cake was dried to yield 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid (61.0 g, 91%). MS m / z (ESI): 265 [M+H] + .
[0236] Step 3: Synthesis of 6-(trifluoromethyl)benzofuran-3(2H)-one
[0237] A mixture of 2-(carboxymethoxy)-4-(trifluoromethyl)benzoic acid (61 g, 230.9 mmol), acetic anhydride (377 mL, 4.02 mol), sodium acetate (28.41 g, 346.4 mmol), and acetic acid (110 mL) was heated to 150°C for 18 hours. After completion of the reaction, the reaction solution was cooled to room temperature, diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the intermediate (42 g) was isolated by silica gel column chromatography. This intermediate was dissolved in methanol (300 mL), 1N hydrochloric acid (300 mL) was added, and the temperature was raised to 100°C for 6 hours. The reaction solution was cooled to room temperature, water was added, and the solution was extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the mixture was slurried with methyl tert-butyl ether to give 6-(trifluoromethyl)benzofuran-3(2H)-one (17.0 g, 36%).
[0238] 1 H NMR (400MHz, CDCl3) δ7.80 (d, J=8.0Hz, 1H), 7.43 (s, 1H), 7.35 (dd, J=8.1, 1.4Hz, 1H), 4.72 (s, 2H).
[0239] Preparation of Intermediate 21, 2-(Trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one
[0240] Step 1: Synthesis of methyl 2-bromo-6-(trifluoromethyl) nicotinate
[0241] Dissolve 2-oxo-6-(trifluoromethyl)-1,2-dihydropyridine-3-carboxylic acid (5.0 g, 24.14 mmol) and pyridine (1.95 mL, 24.14 mmol) in chlorobenzene (50 mL). Slowly add phosphorus oxybromide (4.91 mL, 48.28 mmol) in portions at room temperature. Heat to 120°C and stir for 16 hours. After completion, concentrate the reaction mixture in vacuo. Cool the concentrate to 0°C in an ice bath, then slowly add dry methanol (20 mL) that has been previously cooled with dry ice dropwise. Stir at room temperature for 1 hour. Concentrate the reaction mixture in vacuo to obtain a brown oil. Dilute the oil with water, adjust the pH to 8 with saturated sodium bicarbonate solution, and extract with ethyl acetate three times (50 mL x 3). Wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate. The concentrate was separated by silica gel column chromatography to obtain methyl 2-bromo-6-(trifluoromethyl) nicotinate (5.7 g, 83%). MS m / z (ESI): 284, 286 [M+H] + .
[0242] 1 H NMR (400MHz, CDCl3) δ8.21 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 4.00 (s, 3H).
[0243] Step 2: Synthesis of methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl) nicotinate
[0244] To a solution of methyl 2-bromo-6-(trifluoromethyl)nicotinate (5.7 g, 20.07 mmol) and methyl acrylate (4.52 mL, 50.17 mmol) in toluene (100 mL) and N,N-dimethylformamide (15 mL) were added allylpalladium(II) chloride dimer (0.37 g, 1.00 mmol), tri(o-methylphenyl)phosphine (0.61 g, 2.01 mmol), and sodium carbonate (6.38 g, 60.20 mmol). The mixture was then stirred at 120°C under a nitrogen atmosphere for 16 hours. The reaction mixture was filtered, and the filter cake was washed three times with ethyl acetate (3 × 30 mL). The organic phases were combined and concentrated in vacuo. The concentrate was then separated by silica gel column chromatography to afford methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl)nicotinate (5.1 g, 88%). MS m / z(ESI):290[M+H] + .
[0245] 1 H NMR (400MHz, CDCl3) δ8.46(d,J=15.2Hz,1H),8.40(d,J=8.0Hz,1H),7.70(d,J=8.4Hz,1H),7.26(d,J=2.8Hz,1H),4.01(s,3H),3.84(s,3H).
[0246] Step 3: Synthesis of methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate
[0247] A solution of methyl (E)-2-(3-methoxy-3-oxoprop-1-en-1-yl)-6-(trifluoromethyl) nicotinate (5.1 g, 17.63 mmol) and triphenylphosphine rhodium chloride (1.31 g, 1.41 mmol) in ethanol (50 mL) was stirred at room temperature under a hydrogen atmosphere (15 atm) for 48 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The crude product was separated by silica gel column chromatography to obtain methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate (4.9 g, 95%). MS m / z (ESI): 292 [M+H]+ .
[0248] 1 H NMR (400MHz, CDCl3) δ8.34(d,J=8.0Hz,1H),7.58(d,J=8.0Hz,1H),3.96(s,3H),3.67(s,3H),3.57(t,J=7.2Hz,2H),2.85(t,J=7.2Hz,2H).
[0249] Step 4: Synthesis of 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one
[0250] Sodium methoxide (1.36 g, 25.23 mmol) was added in batches to a solution of methyl 2-(3-methoxy-3-oxopropyl)-6-(trifluoromethyl) nicotinate (4.9 g, 16.82 mmol) in methanol (60 mL), and the reaction solution was stirred at 80°C overnight. After the reaction was completed, the reaction solution was cooled to room temperature and concentrated to obtain a brown solid. The brown solid was dispersed in concentrated hydrochloric acid (60 mL) and stirred at 80°C for 3 hours. The reaction solution was cooled to room temperature, adjusted to pH = 6 with 1M sodium hydroxide solution, and extracted with dichloromethane (2×100 mL). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain a brown solid. The brown solid was separated by silica gel column chromatography to obtain 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one (2.07 g,
[0251] 43%)MS m / z(ESI):202[M+H] + .
[0252] 1 H NMR (400MHz, CDCl3) δ8.21(d,J=8.0Hz,1H),7.73(d,J=8.0Hz,1H),3.42-3.36(m,2H),2.92-2.85(m,2H).
[0253] Preparation of Intermediate 22, 6-(Trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one
[0254] Step 1: Synthesis of ethyl 2-chloro-6-(trifluoromethyl) nicotinate
[0255] Thionyl chloride (3.62 mL, 49.9 mmol) was added dropwise to a nitrogen-protected solution of 2-chloro-6-(trifluoromethyl)nicotinic acid (7.5 g, 33.25 mmol) in ethanol (150 mL) at room temperature. The reaction mixture was then heated to 70°C and stirred for 14 hours. After completion of the reaction, the reaction mixture was concentrated to remove the ethanol, and the residue was dissolved in ethyl acetate (200 mL). The organic phase was washed with water (100 mL x 3), washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The concentrated product was separated by column chromatography (85% ethyl acetate-petroleum ether) to afford ethyl 2-chloro-6-(trifluoromethyl)nicotinate (7.72 g, 92%). MS m / z (ESI): 254 [M+H] + .
[0256] 1 H NMR (400MHz, CDCl3) δ8.30(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),4.46(d,J=7.2Hz,2H),1.43(d,J=7.2Hz,3H).
[0257] Step 2: Synthesis of ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate
[0258] Sodium hydride (15.22 g, 380.5 mmol, 60% purity) was added portionwise to a solution of ethyl glycolate (36.7 mL, 380.5 mmol) in ethylene glycol dimethyl ether (530 mL) at 0°C. The reaction mixture was allowed to warm to room temperature and stirred for 30 minutes. Ethyl 2-chloro-6-(trifluoromethyl)nicotinate (38.6 g, 152.2 mmol) was then dissolved in ethylene glycol dimethyl ether (530 mL) and added dropwise to the reaction mixture. The mixture was allowed to react at 35°C for 2 hours. After completion of the reaction, the reaction mixture was diluted with ethyl acetate and quenched with saturated sodium bicarbonate solution. The organic phase was extracted, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. After concentration, the product was slurried with acetonitrile (300 mL) to yield ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate (29.5 g, 70%).
[0259] 1 H NMR (400MHz, DMSO-d6) δ8.24(d,J=7.6Hz,1H),7.59(d,J=7.6Hz,1H),4.17(q,J=7.2Hz,2H),1.26(t,J=7.2Hz,3H).
[0260] Step 3: Synthesis of 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one
[0261] Ethyl 3-hydroxy-6-(trifluoromethyl)furo[2,3-b]pyridine-2-carboxylate (2.83 g, 10.28 mmol) was dissolved in a mixture of tetrahydrofuran (32.0 mL) and water (8.0 mL), and lithium hydroxide monohydrate (1.73 g, 41.1 mmol) was added. The mixture was heated to 40°C and allowed to react for 2 days. The reaction was complete. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with tetrahydrofuran. The filter cake was then dissolved in a mixture of ethyl acetate and water and acidified to a pH of 6-7 with 1 M hydrochloric acid in an ice-water bath. The layers were separated, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation to yield 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one (1.43 g, 68%). MS m / z (ESI): 204 [M+H]. + .
[0262] 1 H NMR (400MHz, CDCl3) δ8.23 (d, J = 7.6Hz, 1H), 7.52 (d, J = 7.6Hz, 1H), 4.85 (s, 2H).
[0263] Preparation of Intermediate 23, 7-(Trifluoromethyl)isochroman-4-one
[0264] Step 1: Synthesis of 2-((allyloxy)methyl)-1-bromo-4-(trifluoromethyl)benzene
[0265] Dissolve (2-bromo-5-(trifluoromethyl)phenyl)methanol (7.39 g, 29.0 mmol) in tetrahydrofuran (100 mL). Add sodium hydride (1.74 g, 43.5 mmol) at 0°C. After reacting at 0°C for 0.5 hours, add 3-bromoprop-1-ene (2.52 mL, 29.0 mmol) and react at 25°C for 2 hours. Add water (50 mL) to the reaction solution, and extract three times with ethyl acetate (30 mL). The organic phases are combined and concentrated. The crude product is separated by normal phase column chromatography to yield 2-((allyloxy)methyl)-1-bromo-4-(trifluoromethyl)benzene (8.1 g, 95%).
[0266] 1H NMR (400MHz, CDCl3) δ7.98-7.73(m,1H),7.65(d,J=8.4Hz,1H),7.40(dd,J=8.4,2.4Hz,1H),6.1 3-5.90(m,1H),5.49-5.33(m,1H),5.33-5.18(m,1H),4.59(s,2H),4.15(dt,J=5.6,1.6Hz,2H).
[0267] Step 2: Synthesis of 4-methylene-7-(trifluoromethyl)isochromane
[0268] 2-((Allyloxy)methyl)-1-bromo-4-(trifluoromethyl)benzene (8.1 g, 27.4 mmol) was dissolved in N,N-dimethylformamide (160 mL). Cesium carbonate (10.73 g, 32.9 mmol), triphenylphosphine (3.24 g, 12.4 mmol), and palladium acetate (0.92 g, 4.1 mmol) were added and reacted at 90°C for 16 hours. The reaction solution was concentrated, and the crude product was separated by normal phase column chromatography to obtain 4-methylene-7-(trifluoromethyl)isochromane (3.8 g, 65%).
[0269] 1 H NMR (400MHz, CDCl3) δ7.78(d,J=8.4Hz,1H),7.48(d,J=8.4,2.0Hz,1H),7.30( s,1H),5.72(s,1H),5.15(t,J=1.2Hz,1H),4.84(s,2H),4.47(t,J=1.2Hz,2H).
[0270] Step 3: Synthesis of 4-(hydroxymethyl)-7-(trifluoromethyl)isochroman-4-ol
[0271] Dissolve 4-methylene-7-(trifluoromethyl)isochromane (3.8 g, 17.74 mmol) in water (10 mL) and acetone (40 mL). Add potassium osmate dihydrate (0.65 g, 1.77 mmol). Allow to react at 25°C for 5 minutes. Then add N-methylmorpholine oxide (7.27 g, 62.1 mmol) and continue reacting at 25°C for 16 hours. Add saturated sodium thiosulfate solution (50 mL) and extract with ethyl acetate (100 mL). The organic phase is dried by rotary evaporation, and the crude product is separated by normal phase column chromatography to yield 4-(hydroxymethyl)-7-(trifluoromethyl)isochroman-4-ol (3.57 g, 81%).
[0272] 1H NMR (400MHz, CDCl3) δ7.72(d,J=8.4Hz,1H),7.60-7.51(m,1H),7.28(s,1H),4.83(s,2H),4.16(d,J=11.2Hz,1H ), 3.90(dd,J=11.2,6.4Hz,1H), 3.70(ddd,J=11.2,4.8,1.2Hz,1H), 3.63(dd,J=11.2,1.2Hz,1H), 2.87(s,1H).
[0273] Step 4: Synthesis of 7-(trifluoromethyl)isochroman-4-one
[0274] 4-(Hydroxymethyl)-7-(trifluoromethyl)isochroman-4-ol (3.57 g, 14.38 mmol) was dissolved in tetrahydrofuran (50 mL) and water (5 mL). Sodium periodate (10.46 g, 48.90 mmol) was then added and the mixture was allowed to react at 25°C for 16 hours. A saturated sodium thiosulfate solution (40 mL) was added to the reaction solution, and the mixture was extracted three times with ethyl acetate (40 mL). The organic phase was dried by rotary evaporation, and the crude product was separated by normal phase column chromatography to yield 7-(trifluoromethyl)isochroman-4-one (2.88 g, 93%).
[0275] 1 H NMR (400MHz, CDCl3) δ8.16(d,J=8.4Hz,1H),7.68(dd,J=8.4,1.6Hz,1H),7.52(d,J=2.0Hz,1H),4.95(s,2H),4.42(s,2H).
[0276] Preparation of Intermediate 24, 6-(1-methyl-1H-pyrazol-4-yl)benzofuran-3(2H)-one
[0277] 6-Bromobenzofuran-3(2H)-one (1.00 g, 4.69 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.17 g, 5.63 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (343 mg, 0.469 mmol), and potassium carbonate (1.94 g, 14.07 mmol) were dissolved in dioxane (15 mL) and water (5 mL). The mixture was heated to 85 degrees under nitrogen and stirred overnight. After the reaction was completed, the mixture was quenched with water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and filtered. The crude product was separated by silica gel column chromatography to give 6-(1-methyl-1H-pyrazol-4-yl)benzofuran-3(2H)-one (0.8 g, 80%). MS m / z(ESI):215[M+H] + .
[0278] Preparation of Intermediate 25, (S)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine
[0279] Step 1: Synthesis of (R)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine-3-ol
[0280] (R)-2-Methyl-CBS-oxazaborolidine (5.94 g, 21.4 mmol) was dissolved in tetrahydrofuran (1100 mL) and cooled to 0°C. Borane dimethyl sulfide complex (53.5 mL, 107.1 mmol, 2 M in THF) was then added to the solution and stirred for 1 hour. The reaction system was cooled to -70°C, and 6-(trifluoromethyl)furo[2,3-b]pyridin-3(2H)-one (14.5 g, 71.4 mmol) was dissolved in tetrahydrofuran (140 mL) and added dropwise to the reaction system. The mixture was stirred for 1 hour, then heated to -10°C and stirred for another 2 hours. The reaction was checked for completion, quenched with methanol, and stirred at room temperature for 30 minutes. Add 70 mL of aqueous ammonia, stir, pour off the supernatant, concentrate, and separate the residue by silica gel column chromatography (dichloromethane / ethyl acetate = 10 / 1) to obtain (R)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-ol (12.0 g, 82%). MS m / z (ESI): 206 [M+H] + .
[0281] Step 2: Synthesis of (S)-3-azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine
[0282] (R)-6-(Trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-ol (12.0 g, 58.5 mmol) was dissolved in tetrahydrofuran (100 mL), cooled to 0°C, and diphenylphosphoryl azide (15.2 mL, 70.2 mmol) and 1,8-diazobisspiro[5.4.0]undec-7-ene (10.5 mL, 70.2 mmol) were added. The mixture was allowed to warm to room temperature and allowed to react for 18 hours. After completion of the reaction, the reaction solution was diluted with water and extracted with ethyl acetate. The organic phase was dried, concentrated, and then separated by silica gel column chromatography to yield (S)-3-azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine (12.5 g, 93%). MS m / z (ESI): 231 [M+H] + .
[0283] Step 3: Synthesis of (S)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride
[0284] (S)-3-Azido-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridine (12.5 g, 54.3 mmol) was dissolved in tetrahydrofuran (200 mL) and water (6 mL). Triphenylphosphine (42.74 g, 162.9 mmol) was added and the reaction mixture was heated to 50°C for 18 hours. 0.5 M hydrochloric acid was added and the mixture was extracted three times with ethyl acetate. The aqueous phase was separated and concentrated to yield (S)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride (11.0 g, 84%). MS m / z (ESI): 205 [M+H] + .
[0285] Intermediates 26 to 32 can be prepared by selecting corresponding raw materials according to the synthetic method of intermediate 25 in whole or in part:
[0286] Preparation of Intermediate 33, (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine
[0287] Dissolve (S)-6-(Trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine hydrochloride (5.5 g, 22.9 mmol) in dioxane (500 mL), add 4-bromo-1-methyl-1H-pyrazole (4.23 g, 26.3 mmol), methanesulfonic acid (2-di-tert-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (5.45 g, 6.86 mmol), and sodium tert-butoxide (6.59 g, 68.58 mmol). After nitrogen purge three times, heat to 95°C and react for 2 hours. Cool to room temperature, add water, and extract with ethyl acetate. The organic phase obtained by separation was dried and concentrated, and then separated by silica gel column chromatography (PE / EA = 1 / 10) and C18 reverse phase column chromatography (Water (10 mM NH4HCO3)-ACN: 21%-51%) to obtain (S)-N-(1-methyl-1H-pyrazol-4-yl)-6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine (2.40 g, 37%). MS m / z (ESI): 285 [M+H] + .
[0288] 1 H NMR (400MHz, DMSO-d6) δ7.88(d,J=7.4Hz,1H),7.41(d,J=7.4Hz,1H),7.22(d,J=1.0Hz,1H),7.02(d,J=1.0Hz,1H),5.1 9(d,J=8.9Hz,1H), 5.02(td,J=8.5,4.5Hz,1H), 4.84(dd,J=9.6,8.1Hz,1H), 4.38(dd,J=9.6,4.6Hz,1H), 3.71(s,3H).
[0289] Intermediates 34 to 38 can be prepared by selecting corresponding raw materials according to the synthetic method of intermediate 33 in whole or in part:
[0290] Preparation of Intermediate 39, (R)-N-(cyclopropylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine
[0291] (R)-5-(Trifluoromethyl)-2,3-dihydro-1H-inden-1-amine hydrochloride (200 mg, 0.84 mmol) was dissolved in a mixture of dichloromethane (3 mL) and ethanol (3 mL). Potassium acetate (82 mg, 0.84 mmol), cyclopropylcarboxaldehyde (59 mg, 0.84 mmol), acetic acid (5 mg, 0.084 mmol), and sodium triacetoxyborohydride (355 mg, 1.68 mmol) were added and stirred at room temperature overnight. The reaction solution was diluted with dichloromethane and saturated sodium bicarbonate solution, the layers were separated, and the organic phase was concentrated by rotary evaporation. The crude product was isolated by column chromatography (methanol / dichloromethane = 1 / 19) to obtain (R)-N-(cyclopropylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-amine (108 mg, 48%). MS m / z(ESI):256[M+H] + .
[0292] Intermediates 40-43 can be prepared by selecting corresponding raw materials according to the whole or part of the synthesis method of intermediate 39:
[0293] Preparation of Intermediate 44, N-methyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine
[0294] Dissolve 6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine (600 mg, 2.95 mmol) in hexafluoroisopropanol (5 mL), add methyl trifluoromethanesulfonate (727 mg, 4.43 mmol), and stir at room temperature for 2 hours. The reaction mixture is diluted with ethyl acetate and saturated sodium bicarbonate solution, separated, and the organic phase is concentrated by rotary evaporation. The crude product is separated by column chromatography to obtain N-methyl-6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-amine (450 mg, 70%). MS m / z (ESI): 218 [M+H] + .
[0295] Intermediates 45-47 can be prepared by referring to all or part of the synthesis method of Intermediate 44 by selecting the corresponding raw materials:
[0296] Intermediate 48: Preparation of 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole
[0297] Step 1: Synthesis of methyl 4-methyl-5-oxopentanoate
[0298] In an ice-water bath, propionaldehyde (5.0 g, 86.09 mmol) was added to hexahydropyridine (14.66 g, 172.2 mmol) and potassium carbonate (4.76 g, 34.43 mmol). The mixture was stirred vigorously at room temperature for 18 hours. The mixture was filtered, the mother liquor dried over anhydrous sodium sulfate, and filtered again. The filtrate was concentrated and dissolved in acetonitrile (50 mL). Methyl acryloyl ester (14.82 g, 172.2 mmol) was slowly added dropwise. The reaction mixture was heated at reflux for 24 hours. Glacial acetic acid (10.34 g, 172.2 mmol) and water (50 mL) were added, and the mixture was refluxed for another 24 hours. The reaction mixture was diluted with water and extracted with tert-butyl methyl ether. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated by rotary evaporation. The crude product was separated by normal phase column chromatography to yield methyl 4-methyl-5-oxopentanoate (6.22 g, 48%).
[0299] 1 H NMR (400 MHz, CDCl3) δ 9.63 (d, J = 1.6 Hz, 1H), 3.68 (s, 3H), 2.48-2.40 (m, 1H), 2.41-2.35 (m, 2H), 2.10-2.02 (m, 1H), 1.71 (dq, J = 14.3, 7.3 Hz, 1H), 1.14 (d, J = 7.2 Hz, 3H). Step 2: Synthesis of (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one
[0300] To methyl 4-methyl-5-oxopentanoate (6.222 g, 43.16 mmol) in toluene (100 mL) was added (R)-2-amino-2-phenylethan-1-ol (5.92 g, 43.16 mmol). The mixture was heated under reflux for 24 hours and water was removed using a water separator. The reaction solution was concentrated, and the crude product was separated by normal phase column chromatography to give (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one (4.866 g, 46%). MS m / z (ESI): 232 [M+H] + .
[0301] 1 H NMR (400MHz, CDCl3) δ7.33-7.20(m,5H),4.93(dd,J=6.8,1.3Hz,1H),4.44(d,J=8.8Hz,1H),4.17-4.08(m,2H) ,4.01(dd,J=9.0,1.3Hz,1H),2.46-2.28(m,2H),2.02-1.87(m,2H),1.60-1.45(m,1H),1.21(d,J=6.4Hz,3H).
[0302] Step 3: Synthesis of (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one
[0303] To a 200 mL solution of (3R,8S)-8-methyl-3-phenylhexahydro-5H-oxazolo[3,2-a]pyridin-5-one (4.866 g, 21.04 mmol) in anhydrous dichloromethane, triethylsilane (7.34 g, 63.12 mmol) and titanium tetrachloride (17.96 g, 94.68 mmol) were added. The mixture was reacted at 50°C for 24 hours. Additional triethylsilane (7.34 g, 63.12 mmol) and titanium tetrachloride (17.96 g, 94.68 mmol) were added, and the reaction was continued at 50°C for 24 hours. The reaction solution was slowly poured into a saturated sodium bicarbonate solution (500 mL). The aqueous phase was filtered and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column to give (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one (1.54 g, 31%). MS m / z (ESI): 234 [M+H] + .
[0304] Step 4: Synthesis of (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one
[0305] To a solution of (S)-1-((R)-2-hydroxy-1-phenylethyl)-5-methylpiperidin-2-one (10.3 g, 44.15 mmol) in dimethyl sulfoxide (150 mL) was added lithium hydroxide monohydrate (37.05 g, 882.9 mmol). The mixture was reacted at 135°C for 4 days. The mixture was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to yield (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one (7.383 g, 66%). MS m / z (ESI): 216 [M+H] + .
[0306] Step 5: Synthesis of (S)-5-methylpiperidin-2-one
[0307] To a solution of (S)-5-methyl-1-(1-phenylvinyl)piperidin-2-one (7.28 g, 33.81 mmol) in dichloromethane (30 mL) was added TFA (30 mL) and water (3 mL). The reaction was allowed to proceed at 40°C overnight. After concentration, the crude product was separated using a reverse phase column. After freeze-drying, ammonia (3 mL) was added, and the product was concentrated to dryness. The product was then slurried with ethyl acetate and filtered to yield (S)-5-methylpiperidin-2-one (2.52 g, 63%). MS m / z (ESI): 114 [M+H] + .
[0308] 1 H NMR (400MHz, MeOH-d4) δ3.30-3.24 (m, 1H), 2.86 (dd, J = 12.2, 10.1Hz, 1H), 2. 39-2.26(m,2H),1.96-1.80(m,2H),1.54-1.40(m,1H),1.01(d,J=6.5Hz,3H).
[0309] Step 6: Synthesis of tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate
[0310] To a solution of (S)-5-methylpiperidin-2-one (2.02 g, 17.85 mmol) in tetrahydrofuran (25 mL) were added 4-dimethylaminopyridine (327 mg, 2.68 mmol) and di-tert-butyl dicarbonate (6.22 g, 26.78 mmol). The mixture was stirred at 25°C overnight. The reaction solution was concentrated, diluted with dichloromethane, and washed with 5% potassium bisulfate solution. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to yield tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate (3.48 g, 70%). MS m / z (ESI): 214 [M+H] + .
[0311] 1 H NMR(400MHz, CDCl3) δ3.83-3.75(m,1H),3.11(dd,J=12.7,10.4Hz,1H),2.63-2.53(m,1H),2.53-2.41 (m,1H),2.01-1.93(m,1H),1.92-1.83(m,1H),1.53(s,9H),1.46-1.40(m,1H),1.04(d,J=6.6Hz,3H).
[0312] Step 7: Synthesis of tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate
[0313] To a solution of tert-butyl (S)-5-methyl-2-oxopiperidine-1-carboxylate (1.00 g, 4.69 mmol) in anhydrous tetrahydrofuran (25 mL) was added sodium bis(trimethylsilyl)amide (3.52 mL, 7.03 mmol) at -78°C. The reaction mixture was allowed to react at this temperature for 1 hour. N-phenylbis(trifluoromethanesulfonimide) (2.18 g, 6.10 mmol) was then added. The reaction mixture was slowly heated and stirred at room temperature for 3.5 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column chromatography to yield tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (1.05 g, 62%). MS m / z (ESI): 290 [M+H-56] + .
[0314] 1 H NMR (400MHz, CDCl3) δ5.25(t,J=3.8Hz,1H),3.87(dd,J=12.8,3.3Hz,1H),3.00(dd,J=12.7,9.1Hz ,1H),2.44-2.34(m,1H),1.98-1.88(m,1H),1.88-1.78(m,1H),1.49(s,9H),0.99(d,J=6.6Hz,3H).
[0315] Step 8: Synthesis of tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate
[0316] Tert-butyl (S)-3-methyl-6-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2H)-carboxylate (1.39 g, 4.02 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazole (1.00 g, 3.83 mmol), sodium carbonate (1.01 g, 9.57 mmol), and 1,1'-bis(diphenylphosphinoferrocenedichloridopalladium) (140 mg, 0.191 mmol) were added to 1,4-dioxane (30 mL) and water (10 mL) and reacted at 90°C under nitrogen for 18 hours. The reaction mixture was diluted with ethyl acetate and washed with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The crude product was separated by normal phase column to give tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate (1.01 g, 75%). MS m / z (ESI): 331 [M+H] + .
[0317] Step 9: Synthesis of (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole
[0318] To a solution of tert-butyl (S)-6-(benzo[d]thiazol-5-yl)-3-methyl-3,4-dihydropyridine-1(2H)-carboxylate (1.01 g, 3.05 mmol) in dichloromethane (9 mL) was added trifluoroacetic acid (3 mL, 2.68 mmol). The mixture was allowed to react overnight at 25°C. The reaction mixture was concentrated, diluted with water, adjusted to pH 8 with aqueous ammonia, and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to yield (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (0.70 g, 92%). MS m / z (ESI): 231 [M+H] + .
[0319] Step 10: Synthesis of 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole
[0320] To a solution of (S)-5-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)benzo[d]thiazole (0.70 g, 3.04 mmol) in methanol (5 mL) was added sodium borohydride (308 mg, 9.12 mmol) under ice-water bath. The reaction mixture was stirred at room temperature for 45 minutes. The reaction mixture was concentrated, diluted with water, adjusted to pH 8 with aqueous ammonia, and extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to yield 5-((2R,5S)-5-methylpiperidin-2-yl)benzo[d]thiazole (0.69 g, 98%). MS m / z (ESI): 233 [M+H] + .
[0321] 1 H NMR (400MHz, CDCl3) δ8.98(s,1H),8.15(d,J=1.7Hz,1H),7.88(d,J=8.3Hz,1H),7.56(dd,J=8.3,1.7Hz,1H),3.78(dd,J=11.4,2.6 Hz,1H),3.22-3.13(m,1H),2.48(t,J=11.4Hz,1H),1.97-1.87(m,2H),1.86-1.68(m,2H),1.30-1.19(m,1H),0.92(d,J=6.6Hz,3H).
[0322] Intermediate 49 can be prepared by referring to all or part of the synthesis method of Intermediate 48 by selecting the corresponding raw materials:
[0323] Preparation of Intermediate 50, ((3R,5S)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)morpholine
[0324] Step 1: Synthesis of (R)-1-((tributylstannyl)methoxy)propane-2-amine
[0325] Sodium hydride (204 mg, 5.10 mmol, in 60% kerosene) was dissolved in N,N-dimethylformamide (20 mL). The mixture was cooled in an ice-water bath. (R)-2-aminopropan-1-ol (0.36 mL, 4.64 mmol) was slowly added dropwise. Stir at room temperature for one hour after the addition was complete. The reaction mixture was cooled in an ice-water bath. A solution of tributyl(iodomethyl)stannane (2.00 g, 4.64 mmol) in N,N-dimethylformamide (20 mL) was slowly added dropwise. Stir at room temperature overnight. The reaction mixture was cooled in an ice-water bath and quenched by slowly adding saturated ammonium chloride solution. The layers were separated and the organic phase was washed with saturated brine. The organic phase was concentrated by rotary evaporation, and the crude product was separated by column chromatography to yield (R)-1-((tributylstannyl)methoxy)propan-2-amine (1.30 g, 71%). MS m / z (ESI): 380 [M+H] + .
[0326] Step 2: Synthesis of (R,E)-N-(1-((tributylstannyl)methoxy)propan-2-yl)-1-(5-(trifluoromethyl)pyridin-2-yl)formanimine
[0327] ((R)-1-((tributylstannyl)methoxy)propan-2-amine (800 mg, 2.11 mmol) was dissolved in dichloromethane (20 mL), and 5-trifluoromethylpyridine-2-carbaldehyde (370 mg, 2.11 mmol) and molecular sieves (1.50 g, 3.41 mmol) were added. The mixture was stirred at room temperature overnight. The reaction mixture was filtered, washed with dichloromethane, and the filtrate was concentrated by rotary evaporation to obtain (R,E)-N-(1-((tributylstannyl)methoxy)propan-2-yl)-1-(5-(trifluoromethyl)pyridin-2-yl)methanimine (1100 mg, 97%).
[0328] 1 H NMR (400MHz, CDCl3) δ8.90(dt,J=1.9,0.9Hz,1H),8.40(s,1H),8.14(dt,J=8.3,0.9Hz,1H),7.95(dd,J=8.3,2 .3Hz,1H),3.79-3.63(m,3H),3.43(d,J=6.2Hz,2H),1.48-1.36(m,6H),1.28-1.18(m,9H),0.95-0.81(m,15H).
[0329] Step 3: Synthesis of ((3R,5S)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)morpholine
[0330] (S,S)-2,2'-Isopropylidenebis(4-phenyl-2-oxazoline) (70 mg, 0.21 mmol) was dissolved in hexafluoroisopropanol (10 mL), and copper trifluoromethanesulfonate (151 mg, 0.42 mmol) was added. The mixture was stirred at room temperature overnight. A solution of (R,E)-N-(1-((tributylstannyl)methoxy)propan-2-yl)-1-(5-(trifluoromethyl)pyridin-2-yl)methanimine (1113 mg, 2.08 mmol) in hexafluoroisopropanol (5 mL) was added to the reaction mixture via syringe and stirred at room temperature for 24 hours. The reaction mixture was diluted with dichloromethane and aqueous ammonia solution, separated, and the organic phase was concentrated by rotary evaporation. The crude product was separated by reverse phase column chromatography to obtain ((3R,5S)-3-methyl-5-(5-(trifluoromethyl)pyridin-2-yl)morpholine (195 mg, 37%). MS m / z (ESI): 247 [M+H] + .
[0331] II. Preparation of Examples
[0332] Example 1: Preparation of (R)-4-amino-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0333] 4-Amino-1-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (30.0 mg, 0.12 mmol) and 2-methoxy-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)ethane-1-amine (34.9 mmol, 0.12 mmol) were dissolved in N,N-dimethylacetamide (3 mL), and tripyrrolidinylphosphonium bromide hexafluorophosphate (75.1 mmol, 0.16 mmol) and N,N-diisopropylethylamine (48.0 mg, 0.37 mmol) were added. The mixture was stirred at room temperature overnight. The reaction mixture was stirred at room temperature overnight. After completion, the reaction was quenched with water and extracted three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by silica gel column chromatography [9% methanol-dichloromethane] to obtain the crude product. This was then separated by reverse phase column chromatography [50% acetonitrile-10 nM aqueous ammonium bicarbonate solution] and lyophilized to obtain (R)-4-amino-1-methyl-N-(1-(pyrimidin-2-yl)ethyl)-N-((5-(trifluoromethyl)pyridin-2-yl)methyl)imidazo[1,5-a]quinoxaline-8-carboxamide (18 mg, 28%). MS m / z (ESI): 507 [M+H] + .
[0334] 1H NMR(400MHz, DMSO-d6)δ8.88-8.76(m,3H),8.29(s,1H),8.11(dd,J=8.5,2.4Hz,1H),7.80(s,1H),7.61-7.47( m,3H),7.41(t,J=4.9Hz,1H),7.30(s,2H),5.56(s,1H),5.00-4.47(m,2H),2.89(s,3H),1.60(d,J=7.0Hz,3H).
[0335] Example 2: Preparation of (S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide
[0336] Step 1: Synthesis of 4-amino-7-fluoro-1-methylimidazo[1,5-a]quinoxaline-8-carbonyl chloride hydrochloride
[0337] 4-Amino-7-fluoro-1-methylimidazo[1,5-a]quinoxaline-8-carboxylic acid (100 mg, 0.38 mmol) was placed in dichloromethane (10 mL). 1,4-dioxane hydrochloride (0.5 mL, 2.0 mmol, 4 mol / L) was added and stirred at room temperature for half an hour. The reaction solution was concentrated to dryness by rotary evaporation under reduced pressure. Thionyl chloride (1.0 mL, 13.79 mmol) was added to the residue and the reaction was stirred at 65°C overnight. The reaction solution was concentrated by rotary evaporation under reduced pressure. Dry dichloromethane (5 mL) was added to the residue and the mixture was concentrated by rotary evaporation to obtain 4-amino-7-fluoro-1-methylimidazo[1,5-a]quinoxaline-8-carbonyl chloride hydrochloride (118 mg, 99%). MS m / z (ESI): 275 [M+H] + .
[0338] Step 2: Synthesis of (S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-yl)-1H-pyrazolo[4,3-c]quinoline-8-carboxamide
[0339] 4-Amino-7-fluoro-1-methylimidazo[1,5-a]quinoxaline-8-carbonyl chloride hydrochloride (77 mg, 0.24 mmol) was placed in dichloroethane (6 mL), and pyridine (0.10 mL, 1.22 mmol) and (S)-1-methyl-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)-1H-pyrazol-4-amine (69 mg, 0.24 mmol) were added. The mixture was stirred at 60°C for 5 hours. After completion of the reaction, the reaction mixture was concentrated by rotary evaporation, and the crude product was separated by reverse phase column chromatography to obtain ((S)-4-amino-7-fluoro-1-methyl-N-(1-methyl-1H-pyrazol-4-yl)-N-(6-(trifluoromethyl)-2,3-dihydrobenzofuran-3-yl)imidazo[1,5-a]quinoxaline-8-carboxamide (32 mg, 25%). MS m / z (ESI): 526 [M+H] + .
[0340] 1 H NMR (400MHz, DMSO-d6) δ7.96(d,J=6.2Hz,1H),7.80(s,1H),7.71(d,J=7.9Hz,1H),7.46(s,2H),7.41(s,1H),7.33(d,J=7.9Hz,1H),7.11( s,1H),6.99(d,J=10.6Hz,1H),6.87(s,1H),6.61(s,1H),4.88(t,J=10.0Hz,1H),4.67(dd,J=10.6,4.0Hz,1H),3.50(s,3H),2.93(s,3H).
[0341] Examples 3 to 233 can be prepared by selecting corresponding raw materials according to all or part of the synthesis method of Example 1 or Example 2:
[0342] The NMR data of the compound prepared in the above example are as follows:
[0343] Biological test evaluation
[0344] 1. Human Colon Cancer HCT116 Cell Proliferation Inhibition Assay
[0345] 1. HCT 116 MTAP knockout and MTAP wild-type cells were plated in 96-well flat-bottom plates and cultured overnight in McCoy's 5A medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO2.
[0346] 2. On the second day, dissolve the compound in DMSO, dilute the compound with DMSO and culture medium in turn and transfer to the cell plate. The final concentration of the compound is 10 μM, 4-fold dilution, 9 concentration gradients plus DMSO control.
[0347] 3. Remove cells that have not been treated with the compound and detect cell viability using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the kit instructions. Then place the cell plate on the EnVision Multilabel Reader to detect the luminescence signal.
[0348] 4. At the same time, the cell plates treated with the compounds were cultured at 37°C and 5% CO2 for 6 consecutive days.
[0349] 5. Then, use CellTiter-Glo to detect cell activity.
[0350] 6. Finally, the dose-response curve was drawn using the four-parameter dose-response curve module of GraphPad Prism v 9.2.0 software and the IC of proliferation inhibition was calculated. 50 (Unit: nM). The test results are as follows:
[0351] Table 1: Biological test results
[0352] From the biological activity data of the compounds in the specific examples, it can be seen that the series of compounds of the present invention have a strong inhibitory effect on the proliferation of human colon cancer HCT116MTAP knockout cells at the cellular level and have a high selectivity for wild-type cells.
[0353] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in, is a double bond or a single bond; X1 is C or N, X2 is C or N, provided that at least one of X1 and X2 is N; X3 is CR5 or N, X4 is CR6 or N, X5 is CR7 or N, X6 is CR8 or N, X7 is CR9 or N, X8 is CR 10 or N; R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R is -Ring A-(R a ) n , Ring A is selected from C 3-12 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the C 3-12 The cycloalkyl group or the 4-10 membered heterocyclic group is optionally further fused to a C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 Aryl or 5-10 membered heteroaryl is optionally further fused to 5-10 membered heteroaryl, C 3-12 Cycloalkyl or 4-10 membered heterocyclic group, Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 , or, when n ≥ 2, two R a Together with the carbon atom to which it is directly attached, it forms C(O), and the above groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -S(O) r R 15 、-OR 14 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 , the C 3-12 The cycloalkyl group or the 3-12 membered heterocyclic group is optionally further fused to a C 6-10 Aryl or 5-10 membered heteroaryl, the C 6-10 The aryl or 5-10 membered heteroaryl is optionally further fused to a C 3-12 Cycloalkyl or 4-10 membered heterocyclic group, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl and 3-12 membered heterocyclic group, or, R3 and R4 together with the nitrogen atom to which they are directly connected form a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 Heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 , or, R 11 and R 12 Together with the carbon atom to which it is directly attached, it forms a C 3-12 Cycloalkyl, 4-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, nitro, azido, C 1-10 Alkyl, halogen substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, =O, =S, -C 0-8 Alkyl-SF5, -C 0-8 Alkyl-OS(O)2R 13 、-C 0-8 Alkyl-S(O) r R 13 、-C 0-8 Alkyl-OR 14 、-C 0-8 Alkyl-C(O)OR 14 、-C 0-8 Alkyl-C(O)SR 14 、-C 0-8 Alkyl-SC(O)R 15 、-C 0-8 Alkyl-C(O)R 15 、-C 0-8 Alkyl-OC(O)R 15 、-C 0-8 Alkyl-P(O)(R 15 )2. -C 0-8 Alkyl-NR 16 R 17 、-C 0-8 Alkyl-C(O)NR 16 R 17 and -C 0-8 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 14 independently selected from hydrogen, deuterium, C 1-10 Alkyl, C 2-10 Alkenyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-10 Alkanol The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent, or R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-10 membered heterocyclic group or a 5-10 membered heteroaryl group is formed, wherein the 4-10 membered heterocyclic group or the 5-10 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-10 Alkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen-substituted C 1-10 Alkyl, deuterium substituted C 1-10 Alkyl, C 1-10 Alkoxy, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, 3-12 membered heterocyclic group, 3-12 membered heterocyclic group, C 6-10 Aryl, C 6-10 Aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, C 1-10 Alkyl monosubstituted amino, C 1-10 Alkyl disubstituted amino and C 1-10 substituted with an alkanoyl substituent; m is 0, 1, or 2; n is 0, 1, 2, 3, 4, 5 or 6; Each r is independently 0, 1 or 2.
2. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, hydroxyl, =O, =S, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyl and -NR 16 R 17 substituted by a substituent; Among them, R 16 and R 17 As claimed in claim 1; Preferably, R3 and R4 are each independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 cycloalkyl and 3-6 membered heterocyclic groups.
3. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1; Preferably, R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1.
4. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1; Preferably, R8, R9 and R 10 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1.
5. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 , or, R 11 and R 12 Together with the carbon atom to which it is directly attached, it forms a C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1; Preferably, each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 13 、R 14 、R 15 、R 16 、R 17 and r as claimed in claim 1.
6. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R is -Ring A-(R a ) n , wherein ring A is selected from C 3-6 Cycloalkyl, 4-8 membered heterocyclic group, C 6-8 Aryl or 5-8 membered heteroaryl, the C 3-6 The cycloalkyl group or the 4-8 membered heterocyclic group is optionally further fused to a C 6-8 Aryl or 5-8 membered heteroaryl, the C 6-8 Aryl or 5-8 membered heteroaryl is optionally fused to 5-8 membered heteroaryl, C 3-6 Cycloalkyl or 4-8 membered heterocyclic group, Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、 -C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -S(O) r R 15 、-OR 14 、-C(O)OR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 alkyl-substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -C 0-4 Alkyl-SF5, -C 0-4 Alkyl-OS(O)2R 13 、-C 0-4 Alkyl-S(O) r R 13 、-C 0-4 Alkyl-OR 14 、-C 0-4 Alkyl-C(O)OR 14 、-C 0-4 Alkyl-C(O)SR 14 、-C 0-4 Alkyl-SC(O)R 15 、-C 0-4 Alkyl-C(O)R 15 、-C 0-4 Alkyl-OC(O)R 15 、-C 0-4 Alkyl-P(O)(R 15 )2. -C 0-4 Alkyl-NR 16 R 17 、-C 0-4 Alkyl-C(O)NR 16 R 17 and -C 0-4 Alkyl-N(R 16 )-C(O)R 15 substituted by a substituent; Among them, R 11 、R 12 、R 13 、R 14 、R 15 、R 16 、R 17 , m, n and r as described in claim 1.
7. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R 13 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 14 independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 2-4 Alkenyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 15 independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, cyano, C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 Heterocyclic oxy group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR 16 R 17 substituted by a substituent; Each R 16 and R 17 are independently selected from hydrogen, deuterium, hydroxyl, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C 1-4 Alkanoyl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, =O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 substituted with an alkanoyl substituent, or R 16 and R 17 Together with the nitrogen atom directly connected thereto, a 4-8 membered heterocyclic group or a 5-8 membered heteroaryl group is formed, wherein the 4-8 membered heterocyclic group or the 5-8 membered heteroaryl group is optionally further substituted with one or more selected from deuterium, halogen, hydroxyl, ═O, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, halogen-substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, C 1-4 Alkyl monosubstituted amino, C 1-4 Alkyl disubstituted amino and C 1-4 The alkanoyl group is substituted with an alkanoyl substituent.
8. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following structure: wherein X3 is CR5 or N, X4 is CR6 or N, X5 is CR7 or N, X6 is CR8 or N, and X7 is CR9 or N; R1 is -(CR 11 R 12 ) m -R, or, R1 and R2 together with the nitrogen atom to which they are directly connected form a ring B, said ring B being a 4-10 membered nitrogen-containing heterocyclic group or a 5-10 membered nitrogen-containing heteroaryl group, said ring B being optionally further substituted with one or more selected from R, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; R is the following structure: Among them, Y1, Y2, Y4, Y5, Y6, Y7, Y8, Y9, Y 10 、Y 11 、Y 12 、Y 13 Each independently CR a or N; Y3 is -O-, -S- or -NR a3 -; Z is -O-, -S-, or -CR a1 R a2 -、-CR a1 R a2 -O- or -NR a3 -, p is 0, 1, 2 or 3; Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R a1 and R a2 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R a3 are each independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 and -C(O)NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; Each R2 is independently selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 Alkyl substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 substituted by a substituent; R5, R6 and R7 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、 -O-C(O)R 15 ,-P(O)(R 15 )2,-NR 16 R 17 ,-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; R8 and R9 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OS(O)2R 13 、-S(O) r R 13 、-OR 14 、-C(O)OR 14 、-C(O)SR 14 、-SC(O)R 15 、-C(O)R 15 、-OC(O)R 15 、-P(O)(R 15 )2、-NR 16 R 17 、-C(O)NR 16 R 17 and -N(R 16 )-C(O)R 15 ; Among them, R 13 、R 14 、R 15 、R 16 、R 17 , r and m as described in claim 1.
9. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following compound structures of formula (III1) and formula (III2): wherein each X3 is independently CR5 or N, each X4 is independently CR6 or N, each X5 is independently CR7 or N, and each X6 is independently CR8 or N; In the structure of the compound of formula (III2), ring B is a 4-10 membered nitrogen-containing heterocyclic group, and the 4-8 membered nitrogen-containing heterocyclic group is optionally further substituted by one or more selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, -SF5 and -NR 16 R 17 substituted by a substituent; Each R is independently the following structure: Among them, Y1, Y2, Y6, Y7, Y8, Y9, Y 10 and Y 11 Each independently CR a or N; Y3 is -O- or -S-; Z is -O-, -S-, -CH2- or -CH2-O-, p is 0, 1, 2 or 3, Each R a are each independently selected from hydrogen, deuterium, halogen, cyano, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, -SF5, -OR 14 、-C(O)OR 14 、-C(O)SR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 The above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, =O, =S, -SF5, -OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl and 5-8 membered heteroaryl, the above groups are independently optionally further substituted with one or more selected from deuterium, halogen, cyano, C 1-4 Alkyl, halogen substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 6-8 Aryl, 5-8 membered heteroaryl, halogen substituted C 3-6 Cycloalkyl, halogen-substituted 3-6 membered heterocyclic group, halogen-substituted C 6-8 Aryl, halogen-substituted 5-8 membered heteroaryl, C 1-4 Alkyl substituted C 3-6 Cycloalkyl, C 1-4 Alkyl substituted 3-6 membered heterocyclic group, C 1-4 Alkyl substituted C 6-8 Aryl, C 1-4 Alkyl substituted 5-8 membered heteroaryl, (2-(trimethylsilyl)ethoxy)methyl, =O, =S, -SF5, -OR 14 、-C(O)OR 14 、-C(O)R 15 、-OC(O)R 15 and -NR 16 R 17 substituted by a substituent; Each of R5, R6 and R7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ; Each R 11 and R 12 are each independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5 and -NR 16 R 17 ; Among them, R 14 、R 15 、R 16 and R 17 As claimed in claim 1.
10. The compound of formula (I) according to claim 9, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Contained in the structure Selected from the following structures: Each X6 is independently CR8 or N; Each of R5, R6 and R7 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, halogen substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5, amino, single C 1-4 Alkyl substituted amino and di-C 1-4 Alkyl substituted amino group; Each R8 is independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, C 1-4 Alkyl, C 1-4 Alkoxy, Halogen-substituted C 1-4 Alkyl, halogen substituted C 1-4 Alkoxy, deuterium substituted C 1-4 Alkyl, deuterium substituted C 1-4 Alkoxy, C 2-4 Alkenyl, C 2-4 Alkynyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, C 6-8 Aryl, C 6-8 Aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, -SF5, amino, single C 1-4 Alkyl substituted amino and di-C 1-4 Alkyl substituted amino group.
11. The compound of formula (I) according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following formula (IV 1-1 )、(Ⅳ 1-2 )、(Ⅳ 2-1 ) or (Ⅳ 2-2 )Compound structure: wherein each X4 is independently CR6 or N; each X5 is independently CR7 or N; Y6 and Y7 are each independently CH or N; Z is O or CH2; p is 1 or 2; Formula (Ⅳ 2-1 ) or (Ⅳ 2-2 ) In the compound structure, ring B and its substituents are selected from the following structures: q is selected from 0, 1 or 2; Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, methoxy, ethoxy, cyclopropyl and -SF5; Each R" is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl and cyclopropyl; Each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl and triazinyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl and triazinyl. substituted by alkyl, isopropyl, n-butyl, isobutyl, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, phenyl, pyrazolyl, 2-(trimethylsilyl)ethoxy, methyl-substituted pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyridyl, fluorine-substituted pyridyl, pyridazinyl, pyrimidinyl, triazinyl, =O, =S, -SF5, hydroxy, methoxy, ethoxy, cyclopropyloxy, cyclobutyloxy, amino, methylamino, and dimethylamino; Each R a each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy, ethoxy, trifluoromethyl, difluoromethyl, trideuteromethyl, dideuteromethyl, trifluoromethoxy, trideuteromethoxy, vinyl, ethynyl, cyclopropyl, cyclobutyl, methyl-substituted cyclopropyl, methyl-substituted cyclobutyl, cyclopropyloxy, cyclobutyloxy, oxetanyl, azetidinyl, tetrahydropyrrolyl, piperidinyl, methyl-substituted piperidinyl, phenyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, thiazolyl, pyrimidinyl, methyl-substituted pyrazolyl, -SF5, hydroxyl, amino, methylamino, dimethylamino, dimethylaminomethyl and dimethylaminoethyl; Each R6 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl; Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl; Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, hydroxy, methyl, ethyl, n-propyl, isopropyl, methoxy, trifluoromethyl, trifluoromethoxy, trideuteriomethyl, trideuteriomethoxy and cyclopropyl; R 11 and R 12 Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
12. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Contained in the structure Selected from the following structures: R7 is selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; R8 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
13. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Formula (Ⅳ 1-2 ) and (Ⅳ 2-1 ) contained in the compound structure Selected from the following structures: Formula (Ⅳ 1-1 ) contained in the compound structure Selected from the following structures: Each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, isopropyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5.
14. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrazolyl, imidazolyl, thiazolyl, pyridyl and pyrimidinyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, tris(2-hydroxy-4-oxo-1-yl)-1-oxo ... substituted by fluoromethyl, difluoromethyl, trideuteriomethyl, dideuteriomethyl, cyclopropyl, cyclobutyl, cyclopentyl, bicyclo[1.1.1]pentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrazolyl, (2-(trimethylsilyl)ethoxy)methyl substituted pyrazolyl, imidazolyl, thiazolyl, pyridinyl, fluoro-substituted pyridinyl, pyrimidinyl, methoxy, ethoxy and cyclopropyloxy.
15. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Each R2 is independently selected from hydrogen, deuterium, methyl, ethyl, trifluoromethyl, trifluoroethyl, trideuteriomethyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl or the following substituent structure:
16. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following formula (V 1-1-1 ) or formula (V 1-1-2 )Compound structure: wherein each Y7 is independently CH or N; each Z is independently O or CH2; each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5; Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl; wherein R2 is as described in claim 11.
17. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following formula (V 1-2-1 ) or formula (V 1-2-2 )Compound structure: Wherein, Y6 and Y7 are each independently CH or N; R a is selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl, and -SF5; R7 is selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; R8 is selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuterium and cyclopropyl.
18. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following formula (V 2-1-1 ) or formula (V 2-1-2 )Compound structure: Among them, each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl and -SF5; Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl.
19. The compound of formula (I) according to claim 11, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: The compound of formula (I) has the following formula (V 2-2-1 ) or formula (V 2-2-2 )Compound structure: Among them, each R a Each is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, methoxy, trifluoromethyl, trideuteriomethyl, trifluoromethoxy, trideuteriomethoxy, cyclopropyl, pyrazolyl, methyl-substituted pyrazolyl, methyl-substituted piperidinyl, dimethylaminoethyl and -SF5; Each R' is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R7 is independently selected from hydrogen, deuterium, fluorine, chlorine, methyl, trifluoromethyl, trideuterium and cyclopropyl; Each R8 is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl and cyclopropyl.
20. The compound of formula (I) according to any one of claims 1 to 19, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:
21. A pharmaceutical composition comprising the compound of formula (I) according to any one of claims 1 to 20, its stereoisomers or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
22. Use of the compound of formula (I) according to any one of claims 1 to 20, its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of a drug for treating MATP-related tumors.
23. The use according to claim 22, characterized in that The tumor is selected from the group consisting of cell tumors, lymphomas, leukemias, osteomas, malignant teratomas, intraepithelial carcinomas, adenomas, fibromas, melanomas, fallopian tube cancer, bladder cancer, teratomas, embryonal carcinomas, choriocarcinomas, lipomas, liver cancer, bile duct cancer, lung cancer, gastric cancer, hemangiomas, gallbladder cancer, ampullary cancer, malignant melanomas, nevi, dysplastic nevi, myeloproliferative diseases, Hodgkin's disease, chordomas, myxomas, rhabdomyomas, leiomyomas, hamartomas, mesotheliomas, insulinomas, glucagonomas, gastrinomas, carcinoid tumors, viper tumors, granulomas, xanthomas, osteitis deformans, ependymomas, neurilemmomas, congenital tumors, meningiomas, gliomas, skin cancers, head and neck cancers, and sarcomas.
24. The use according to claim 22, characterized in that The cell tumor is selected from the group consisting of granulosa-thecoma, Sertoli cell tumor, germ cell tumor, Wilms tumor, seminoma, hepatoblastoma, malignant fibrous histiocytoma, chondroblastoma, giant cell tumor, astrocytoma, medulloblastoma, glioblastoma multiforme, oligodendroglioma, retinoblastoma, squamous cell carcinoma, clear cell carcinoma, transitional cell carcinoma, interstitial cell carcinoma, and basal cell carcinoma; The lymphoma is selected from malignant lymphoma and non-Hodgkin's lymphoma; The leukemia is selected from acute and chronic myeloid leukemia, acute lymphocytic leukemia and chronic lymphocytic leukemia; The bone tumor is selected from osteochondroma, benign enchondroma, osteoid osteoma, enchondromatous hamartoma, multiple myeloma and skull tumor; The adenoma is selected from the group consisting of fibroadenoma, adenomatoid tumor, hepatocellular adenoma, bronchial adenoma, tubular adenoma, villous adenoma, breast cancer, pancreatic cancer, endometrial adenocarcinoma, prostate cancer, ductal adenocarcinoma and colorectal adenocarcinoma; The fibroma is selected from the group consisting of fibroma, chondromyxofibroma, neurofibroma and spinal neurofibroma; The myeloproliferative disease is selected from the group consisting of multiple myeloma and myelodysplastic syndrome; The lung cancer is selected from bronchogenic carcinoma and alveolar carcinoma; The sarcoma is selected from the group consisting of fibrosarcoma, botryoid sarcoma, angiosarcoma, Kaposi's sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, rhabdomyosarcoma, liposarcoma, leiomyosarcoma, and meningeal sarcoma.
25. The compound of formula (I) according to any one of claims 1 to 20, its stereoisomer or a pharmaceutically acceptable salt thereof, for use as a PRMT5 inhibitor.
Citation Information
Cited By
Novel PRMT5 inhibitor and application thereof
CN118613482A
Novel PRMT5 inhibitor and application thereof
CN119585276A
Novel prmt5 inhibitors and uses thereof
CN119585276B
